{"id":"sodium-tetradecyl-sulfate","rwe":[{"pmid":"41850524","year":"2026","title":"Sodium Tetradecyl Sulfate Sclerotherapy Foam: Stability, Cost, and Clinical Relevance of Filters Versus Ethiodized Oil.","finding":"","journal":"Journal of vascular and interventional radiology : JVIR","studyType":"Clinical Study"},{"pmid":"41846626","year":"2026","title":"Multiple Ganglion Cysts of the Wrist and Leg in a 70-Year-Old Female: A Case Report.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41798415","year":"2026","title":"Viscosity-Augmented Percutaneous Sclerotherapy for Recurrent Thoracic Spinal Aneurysmal Bone Cyst: A Technical Innovation to Mitigate Venous Washout.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"41796858","year":"2026","title":"Sclerosing and Embolizing Gel for Venous Embolization: Feasibility Study in a Porcine Model.","finding":"","journal":"Journal of vascular and interventional radiology : JVIR","studyType":"Clinical Study"},{"pmid":"41541999","year":"2025","title":"Short-Term Outcome of Foam Sclerotherapy With Sodium Tetradecyl Sulphate for the Treatment of Venous Malformation in Dhaka, Bangladesh: A Single-Centre Experience.","finding":"","journal":"Cureus","studyType":"Clinical Study"}],"_fda":{"id":"5c279d1b-193e-46d3-a28c-43a0d3f14f96","set_id":"997394e1-ec1f-4093-e053-2a95a90a0ea0","openfda":{"unii":["Q1SUG5KBD6"],"route":["INTRAVENOUS"],"rxcui":["204491"],"spl_id":["5c279d1b-193e-46d3-a28c-43a0d3f14f96"],"brand_name":["Sodium Tetradecyl Sulfate"],"spl_set_id":["997394e1-ec1f-4093-e053-2a95a90a0ea0"],"package_ndc":["24201-201-01","24201-201-05"],"product_ndc":["24201-201"],"generic_name":["SODIUM TETRADECYL SULFATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SODIUM TETRADECYL SULFATE"],"manufacturer_name":["Hikma Pharmaceuticals USA Inc."],"application_number":["ANDA209937"],"is_original_packager":[true]},"version":"5","warnings":["WARNINGS Sodium tetradecyl sulfate injection should only be administered by a healthcare professional experienced in venous anatomy and the diagnosis and treatment of conditions affecting the venous system and familiar with proper injection technique. Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, extreme care in intravenous needle placement and using the minimal effective volume at each injection site are important. Emergency resuscitation equipment should be immediately available. Allergic reactions, including fatal anaphylaxis, have been reported. As a precaution against anaphylactic shock, it is recommended that 0.5 mL of sodium tetradecyl sulfate injection be injected into a varicosity, followed by observation of the patient for several hours before administration of a second or larger dose. The possibility of an anaphylactic reaction should be kept in mind, and the physician should be prepared to treat it appropriately. Because of the danger of thrombosis extension into the deep venous system, thorough preinjection evaluation for valvular competency should be carried out and slow injections with a small amount (not over 2 mL) of the preparation should be injected into the varicosity. Deep venous patency must be determined by noninvasive testing such as duplex ultrasound. Venous sclerotherapy should not be undertaken if tests such as Trendelenberg and Perthes, and angiography show significant valvular or deep venous incompetence. The development of deep vein thrombosis and pulmonary embolism have been reported following sclerotherapy treatment of superficial varicosities. Patients should have post-treatment follow-up of sufficient duration to assess for the development of deep vein thrombosis. Embolism may occur as long as four weeks after injection of sodium tetradecyl sulfate. Adequate post-treatment compression may decrease the incidence of deep vein thrombosis. Arterial Embolism Stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function have been reported in close temporal relationship with STS administration. These events may be caused by air embolism when using the product foamed with room air (high nitrogen concentration) or thromboembolism. The safety and efficacy of STS foamed with room air has not been established and its use should be avoided."],"pregnancy":["PREGNANCY Teratogenic Effects Animal reproduction studies have not been conducted with sodium tetradecyl sulfate injection. It is also not known whether sodium tetradecyl sulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. sodium tetradecyl sulfate injection should be given to a pregnant woman only if clearly needed and the benefits outweigh the risks."],"description":["DESCRIPTION Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. The structural formula is as follows: C 14 H 29 NaSO 4 7-Ethyl-2-methyl-4-hendecanol sulfate sodium salt MW 316.44 Sodium tetradecyl sulfate injection is a sterile nonpyrogenic solution for intravenous use as a sclerosing agent. 3% 60 mg/2 mL (30 mg/mL): Each mL contains sodium tetradecyl sulfate 30 mg, benzyl alcohol 0.02 mL and dibasic sodium phosphate, anhydrous 9 mg in Water for Injection. pH 7.9; monobasic sodium phosphate and/or sodium hydroxide added, if needed, for pH adjustment. Sodium Tetradecyl Sulfate Structural Formula"],"precautions":["PRECAUTIONS GENERAL Extreme caution must be exercised in the presence of underlying arterial disease such as marked peripheral arteriosclerosis or thromboangiitis obliterans (Buerger’s Disease)."],"how_supplied":["HOW SUPPLIED Sodium tetradecyl sulfate injection, 3%, 60 mg/2 mL (30 mg/mL) is a sterile nonpyrogenic solution for intravenous use. NDC 24201-201-05 Carton containing 5 x 2 mL multiple-dose vials."],"pediatric_use":["PEDIATRIC USE Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20240626","nursing_mothers":["NURSING MOTHERS It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sodium tetradecyl sulfate injection is administered to a nursing woman."],"adverse_reactions":["ADVERSE REACTIONS Local reactions consisting of pain, urticaria or ulceration may occur at the site of injection. A permanent discoloration may remain along the path of the sclerosed vein segment. Sloughing and necrosis of tissue may occur following extravasation of the drug. (See WARNINGS section.) Allergic reactions such as hives, asthma, hay fever and anaphylactic shock have been reported. Mild systemic reactions that have been reported include headache, nausea and vomiting. (See WARNINGS section.) At least six deaths have been reported with the use of sodium tetradecyl sulfate injection. Four cases of anaphylactic shock leading to death have been reported in patients who received sodium tetradecyl sulfate injection. One of these four patients reported a history of asthma, a contraindication to the administration of sodium tetradecyl sulfate injection. (See WARNINGS section.) One death has been reported in a patient who received sodium tetradecyl sulfate injection and who had been receiving an antiovulatory agent. Another death (fatal pulmonary embolism) has been reported in a 36-year-old female treated with sodium tetradecyl acetate and who was not taking oral contraceptives. Cerebrovascular accident, myocardial infarction To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800 FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Sodium tetradecyl sulfate injection is contraindicated in previous hypersensitivity reactions to the drug; in acute superficial thrombophlebitis; valvular or deep vein incompetence; huge superficial veins with wide open communications to deeper veins; phlebitis migrans; acute cellulitis; allergic conditions; acute infections; varicosities caused by abdominal and pelvic tumors unless the tumor has been removed; bedridden patients; such uncontrolled systemic diseases as diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias and acute respiratory or skin diseases."],"drug_interactions":["DRUG INTERACTIONS No well-controlled studies have been performed on patients taking antiovulatory agents. The physician must use judgment and evaluate any patient taking antiovulatory drugs prior to initiating treatment with sodium tetradecyl sulfate injection. (See ADVERSE REACTIONS section.) Heparin should not be included in the same syringe as sodium tetradecyl sulfate injection, since the two are incompatible."],"general_precautions":["GENERAL Extreme caution must be exercised in the presence of underlying arterial disease such as marked peripheral arteriosclerosis or thromboangiitis obliterans (Buerger’s Disease)."],"teratogenic_effects":["Teratogenic Effects Animal reproduction studies have not been conducted with sodium tetradecyl sulfate injection. It is also not known whether sodium tetradecyl sulfate injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. sodium tetradecyl sulfate injection should be given to a pregnant woman only if clearly needed and the benefits outweigh the risks."],"storage_and_handling":["STORAGE Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Sodium tetradecyl sulfate injection is a sclerosing agent. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent."],"indications_and_usage":["INDICATIONS AND USAGE Sodium tetradecyl sulfate injection is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit- to-risk ratio should be considered in selected patients who are great surgical risks."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Do not use if precipitated or discolored. Sodium tetradecyl sulfate injection is for intravenous use only. The strength of solution required depends on the size and degree of varicosity. In general, the 1% solution will be found most useful with the 3% solution preferred for larger varicosities. The dosage should be kept small, using 0.5 mL to 2 mL (preferably 1 mL maximum) for each injection, and the maximum single treatment should not exceed 10 mL."],"spl_product_data_elements":["Sodium Tetradecyl Sulfate Sodium Tetradecyl Sulfate SODIUM TETRADECYL SULFATE TETRADECYL HYDROGEN SULFATE (ESTER) BENZYL ALCOHOL SODIUM PHOSPHATE, DIBASIC, ANHYDROUS WATER"],"animal_pharmacology_and_or_toxicology":["ANIMAL TOXICOLOGY The intravenous LD 50 of sodium tetradecyl sulfate in mice was reported to be 90 ± 5 mg/kg. In the rat, the acute intravenous LD 50 of sodium tetradecyl sulfate was estimated to be between 72 mg/kg and 108 mg/kg. Purified sodium tetradecyl sulfate was found to have an LD 50 of 2 g/kg when administered orally by stomach tube as a 25% aqueous solution to rats. In rats given 0.15 g/kg in drinking water for 30 days, no appreciable toxicity was seen, although some growth inhibition was discernible. Manufactured for: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 USA Manufactured by: Hikma Farmacêutica (Portugal), S.A. Estrada do Rio da Mó, 8, 8A e 8B - Fervença 2705-906 Terrugem SNT, PORTUGAL REVISED December 2023 PIN657-WES/1"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 30 mg/mL Carton Label NDC 24201- 201 -01 2 mL Multiple-Dose Vial Sodium Tetradecyl Sulfate 3% Injection 60 mg/2 mL (30 mg/mL) FOR IV USE ONLY DO NOT USE IF PRECIPITATED Rx Only NDC 24201- 201 -05 5 x 2 mL Multiple-Dose Vial Sodium Tetradecyl Sulfate 3% Injection 60 mg/2 mL (30 mg/mL) FOR IV USE ONLY DO NOT USE IF PRECIPITATED Rx Only unit Label carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY When tested in the L5178YTK +/- mouse lymphoma assay, sodium tetradecyl sulfate did not induce a dose-related increase in the frequency of thymidine kinase-deficient mutants and, therefore, was judged to be nonmutagenic in this system. However, no long-term animal carcinogenicity studies with sodium tetradecyl sulfate have been performed."]},"tags":[{"label":"tetradecyl sulfate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C05BB04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Venous varices","category":"indication"},{"label":"Elkins Sinn","category":"company"},{"label":"Approved 1940s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Pharmaceutical Solutions","category":"pharmacology"},{"label":"Sclerosing Solutions","category":"pharmacology"},{"label":"Surface-Active Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Anaphylactic shock","drugRate":"reported","severity":"unknown"},{"effect":"Myocardial infarction","drugRate":"reported","severity":"unknown"},{"effect":"Cerebrovascular accident","drugRate":"reported","severity":"unknown"},{"effect":"Fatal pulmonary embolism","drugRate":"reported","severity":"unknown"},{"effect":"Death","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Vomiting","drugRate":"reported","severity":"mild"},{"effect":"Urticaria","drugRate":"reported","severity":"mild"},{"effect":"Ulceration","drugRate":"reported","severity":"mild"},{"effect":"Pain","drugRate":"reported","severity":"mild"},{"effect":"Asthma","drugRate":"reported","severity":"unknown"},{"effect":"Hay fever","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute tuberculosis","Arteriosclerotic vascular disease","Bed-ridden","Diabetic - poor control","Disease of blood AND/OR blood-forming organ","Exacerbation of asthma","Incompetence of any valvular structure","Infection of skin AND/OR subcutaneous tissue","Infectious disease","Neoplasm","Peripheral venous insufficiency","Sepsis syndrome","Thromboangiitis obliterans","Thrombophlebitis","Thrombophlebitis migrans","Thyrotoxicosis"],"specialPopulations":{"Pregnancy":"Pregnancy: PREGNANCY. Teratogenic Effects. Animal reproduction studies have not been conducted with sodium tetradecyl sulfate injection. It is also not known whether sodium tetradecyl sulfate injection can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. sodium tetradecyl sulfate injection should be given to pregnant woman only if clearly needed and the benefits outweigh the risks.","Paediatric use":"PEDIATRIC USE. Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Elkins Sinn","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SODIUM TETRADECYL SULFATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:24:30.884215+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:24:36.539730+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM TETRADECYL SULFATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:24:37.269576+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:24:29.686659+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:24:29.686692+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200354/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:24:38.729978+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA209937","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:24:29.686696+00:00"}},"allNames":"sotradecol","offLabel":[],"synonyms":["TETRADECYL HYDROGEN SULFATE (ESTER)","tetradecyl sulfate","sodium tetradecyl sulfate","sodium sotradecol","sotradecol","tetradecyl sulfuric acid"],"timeline":[{"date":"1946-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ELKINS SINN to Elkins Sinn"},{"date":"1946-08-13","type":"positive","source":"DrugCentral","milestone":"FDA approval (Elkins Sinn)"},{"date":"2019-12-09","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 2 manufacturers approved"}],"aiSummary":"Sotradecol (Sodium Tetradecyl Sulfate) is a small molecule drug in the tetradecyl sulfate class, originally developed by Elkins Sinn and currently owned by the same company. It was FDA-approved in 1946 for the treatment of venous varices. As an off-patent medication, Sotradecol is available as a generic product from multiple manufacturers. Key safety considerations include the potential for local irritation and allergic reactions. Sotradecol is used to reduce the appearance of varicose veins.","approvals":[{"date":"1946-08-13","orphan":true,"company":"ELKINS SINN","regulator":"FDA"}],"brandName":"Sotradecol","ecosystem":[{"indication":"Venous varices","otherDrugs":[{"name":"polidocanol","slug":"polidocanol","company":"Chemisch Fbrk Krsslr"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"tetradecyl sulfate","explanation":"","oneSentence":"","technicalDetail":"Sotradecol exerts its effects by causing endothelial damage and activating the coagulation cascade, leading to the formation of thrombi and subsequent reduction in venous diameter."},"commercial":{"launchDate":"1946","_launchSource":"DrugCentral (FDA 1946-08-13, ELKINS SINN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3550","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SODIUM%20TETRADECYL%20SULFATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SODIUM TETRADECYL SULFATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:41:20.007915","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:24:42.396724+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ethanolamine oleate","drugSlug":"ethanolamine-oleate","fdaApproval":"1988-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"polidocanol","drugSlug":"polidocanol","fdaApproval":"2010-03-30","patentExpiry":"Nov 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"phenol","drugSlug":"phenol","fdaApproval":"","relationship":"same-class"},{"drugName":"glucose","drugSlug":"glucose","fdaApproval":"1946-01-17","relationship":"same-class"}],"genericName":"sodium tetradecyl sulfate","indications":{"approved":[{"name":"Venous varices","source":"DrugCentral","snomedId":128060009,"regulator":"FDA","eligibility":"small uncomplicated varicose veins of the lower extremities, competent valves, selected patients who are great surgical risks"}],"offLabel":[],"pipeline":[]},"currentOwner":"Elkins Sinn","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ethanolamine-oleate","brandName":"ethanolamine oleate","genericName":"ethanolamine oleate","approvalYear":"1988","relationship":"same-class"},{"drugId":"polidocanol","brandName":"polidocanol","genericName":"polidocanol","approvalYear":"2010","relationship":"same-class"},{"drugId":"phenol","brandName":"phenol","genericName":"phenol","approvalYear":"","relationship":"same-class"},{"drugId":"glucose","brandName":"glucose","genericName":"glucose","approvalYear":"1946","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07342413","phase":"PHASE4","title":"Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias","status":"NOT_YET_RECRUITING","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2026-02-01","conditions":["Leg Veins"],"enrollment":20,"completionDate":"2026-07-30"},{"nctId":"NCT02557542","phase":"NA","title":"Pilot RCT Evaluating a One Stop Vein Clinic","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2015-10","conditions":["Varicose Veins"],"enrollment":3,"completionDate":"2021-03"},{"nctId":"NCT06192472","phase":"NA","title":"Investigation Into the Pathophysiology and Treatment of Varicose Veins","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2013-04","conditions":["Varicose Veins"],"enrollment":120,"completionDate":"2015-09"},{"nctId":"NCT01347294","phase":"PHASE4","title":"Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2011-08","conditions":["Venous Malformation"],"enrollment":135,"completionDate":"2025-06-30"},{"nctId":"NCT06106971","phase":"PHASE3","title":"Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding","status":"UNKNOWN","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-06-28","conditions":["Gastric Varices Bleeding","Liver Decompensation"],"enrollment":68,"completionDate":"2025-06"},{"nctId":"NCT04132323","phase":"NA","title":"Low Concentrate Detergents Versus Hypertonic Glucose for the Treatment of Telangiectasia","status":"COMPLETED","sponsor":"Derzhavin Tambov State University","startDate":"2019-10-25","conditions":["Sclerotherapy"],"enrollment":172,"completionDate":"2022-03-15"},{"nctId":"NCT02627846","phase":"PHASE4","title":"Laser Ablation Versus Mechanochemical Ablation Trial","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2015-06-01","conditions":["Varicose Veins"],"enrollment":150,"completionDate":"2023-09-04"},{"nctId":"NCT05633277","phase":"NA","title":"Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections","status":"UNKNOWN","sponsor":"ProMedica Health System","startDate":"2020-09-30","conditions":["Venous Reflux","Venous Insufficiency","Venous Ulcer","Venous Disease"],"enrollment":30,"completionDate":"2024-03"},{"nctId":"NCT05597995","phase":"PHASE2","title":"Treatment of Epidermoid Cysts","status":"UNKNOWN","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2022-11-01","conditions":["Epidermoid Cyst"],"enrollment":10,"completionDate":"2023-05-30"},{"nctId":"NCT05500625","phase":"NA","title":"Endoscopic Ultrasound-guided Coil With Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration in Managing Patients With Gastric Varices","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-08-30","conditions":["Gastric Varix"],"enrollment":70,"completionDate":"2025-01-30"},{"nctId":"NCT03311269","phase":"PHASE2","title":"A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency","status":"TERMINATED","sponsor":"Vascular Insights, LLC","startDate":"2017-09-22","conditions":["Venous Insufficiency"],"enrollment":19,"completionDate":"2020-03-27"},{"nctId":"NCT04655417","phase":"EARLY_PHASE1","title":"is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins?","status":"UNKNOWN","sponsor":"Combined Military Hospital, Pakistan","startDate":"2020-02-21","conditions":["Pain","Leg Edema","Cost Effectiveness","Cosmesis"],"enrollment":70,"completionDate":"2021-02-21"},{"nctId":"NCT01408732","phase":"PHASE1,PHASE2","title":"Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2011-02","conditions":["Epistaxis","Hereditary Hemorrhagic Telangiectasia"],"enrollment":18,"completionDate":"2014-09"},{"nctId":"NCT02010437","phase":"PHASE4","title":"RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI","status":"WITHDRAWN","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2014-01","conditions":["Superficial Venous Insufficiency, Varicose Veins"],"enrollment":0,"completionDate":"2015-04"},{"nctId":"NCT03363633","phase":"NA","title":"Perforator Vein Injection for Symptomatic Venous Disease","status":"TERMINATED","sponsor":"Ellen Dillavou","startDate":"2010-03","conditions":["Venous Disease"],"enrollment":12,"completionDate":"2010-10-01"},{"nctId":"NCT03090438","phase":"NA","title":"IVF Outcomes After Varicocele Repair","status":"UNKNOWN","sponsor":"Shaare Zedek Medical Center","startDate":"2017-05","conditions":["Infertility, Male","Varicocele","In Vitro Fertilization"],"enrollment":250,"completionDate":"2021-05"},{"nctId":"NCT01298908","phase":"NA","title":"Comparison of Treatments in Venous Insufficiency","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2007-10","conditions":["Venous Insufficiency"],"enrollment":231,"completionDate":"2015-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"(SOTRADECOL) SODIUM TETRADECYL SULFATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"SODIUM TETRADECYL SULFATE"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Sodium Tetradecyl Sulfate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Sotradecol"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"1154","NDDF":"002554","UNII":"Q1SUG5KBD6","CHEBI":"CHEBI:75273","VANDF":"4019068","INN_ID":"130","RXNORM":"1370424","UMLSCUI":"C0037556","chemblId":"CHEMBL1200354","ChEMBL_ID":"CHEMBL1200354","KEGG_DRUG":"D06882","DRUGBANK_ID":"DB00464","PUBCHEM_CID":"23665770","SNOMEDCT_US":"387320008","SECONDARY_CAS_RN":"300-52-7","MESH_DESCRIPTOR_UI":"D012981"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1946-","companyName":"Elkins Sinn","relationship":"Original Developer"}],"publicationCount":400,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C05BB04","allCodes":["C05BB04"]},"biosimilarFilings":[],"originalDeveloper":"Elkins Sinn","recentPublications":[{"date":"2026 Mar 16","pmid":"41850524","title":"Sodium Tetradecyl Sulfate Sclerotherapy Foam: Stability, Cost, and Clinical Relevance of Filters Versus Ethiodized Oil.","journal":"Journal of vascular and interventional radiology : JVIR"},{"date":"2026 Feb","pmid":"41846626","title":"Multiple Ganglion Cysts of the Wrist and Leg in a 70-Year-Old Female: A Case Report.","journal":"Cureus"},{"date":"2026 Feb","pmid":"41798415","title":"Viscosity-Augmented Percutaneous Sclerotherapy for Recurrent Thoracic Spinal Aneurysmal Bone Cyst: A Technical Innovation to Mitigate Venous Washout.","journal":"Cureus"},{"date":"2026 Mar 6","pmid":"41796858","title":"Sclerosing and Embolizing Gel for Venous Embolization: Feasibility Study in a Porcine Model.","journal":"Journal of vascular and interventional radiology : JVIR"},{"date":"2025 Dec","pmid":"41541999","title":"Short-Term Outcome of Foam Sclerotherapy With Sodium Tetradecyl Sulphate for the Treatment of Venous Malformation in Dhaka, Bangladesh: A Single-Centre Experience.","journal":"Cureus"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Hikma","Mylan Institutional"],"status":"approved","companyName":"Elkins Sinn","companyId":"elkins-sinn","modality":"Small molecule","firstApprovalDate":"1946","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1946-08-13T00:00:00.000Z","mah":"ELKINS SINN","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:24:42.396724+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}